|Mr. Ankit Mahadevia M.D., MBA||Co-Founder, CEO, Pres & Director||721.32k||N/A||1981|
|Ms. Cristina Larkin||Chief Operating Officer||533.8k||N/A||1970|
|Dr. David A. Melnick M.D.||Chief Medical Officer||552.22k||N/A||1952|
|Mr. Joel D. Sendek||CFO, Treasurer & Sec.||N/A||N/A||1967|
|Dr. Thomas R. Parr Jr.||Chief Scientific Officer||N/A||N/A||1954|
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. has collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries, as well as has option to rights to SPR741 in the territory; and collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.